Phuong Khanh Morrow - 23 May 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Ryland Waldinger
Issuer symbol
CRSP
Transactions as of
23 May 2022
Net transactions value
$0
Form type
4
Filing time
24 May 2022, 17:55:33 UTC
Next filing
12 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Award $0 +27,750 $0.000000 27,750 23 May 2022 Common Shares 27,750 Direct F1, F2
transaction CRSP Stock Option (Right to Buy) Award $0 +90,000 $0.000000 90,000 23 May 2022 Common Shares 90,000 $54.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 This restricted stock unit award was granted on May 23, 2022 with respect to 27,750 Common Shares, with (i) one quarter of the shares vesting on May 23, 2023, (ii) one quarter of the shares vesting on May 23, 2024, (iii) one quarter of the shares vesting on May 23, 2025, and (iv) one quarter of the shares vesting on May 23, 2026.
F3 This option was granted on May 23, 2022 with respect to 90,000 Common Shares, with 25% of the shares vesting on May 23, 2023 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.